Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population-Reference-Cited by-同舟云学术

Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population

Published:2021-03-10 Issue:8 Volume:62 Page:1869-1876
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Shirouchi Yuko¹^ORCID,Yokoyama Masahiro¹,Fukuta Takanori¹,Uryu Hideki¹^ORCID,Nishimura Noriko¹,Mishima Yuko¹,Inoue Norihito²,Tsuyama Naoko²,Takeuchi Kengo²³,Terui Yasuhito¹⁴

Affiliation:

1. Department of Hematology Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

2. Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

3. Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

4. Department of Hematology, Saitama Medical University, Iruma-gun, Japan

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1894649

Reference30 articles.

1. A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma

2. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

3. International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

4. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303

5. Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 2 study of pegylated liposomal doxorubicin plus cyclophosphamide, vincristine/vindesine, and prednisone in newly diagnosed PTCL: 8-year results;The Oncologist;2024-05-31

2. T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2022-03